Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dynamix Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Optimization of a lead drug candidate often takes a few years, as companies assess hundreds and sometimes thousands of compounds, seeking just one with the best overall pharmacological profile. By contrast, Dynamix Pharmaceuticals Ltd. says its structure-based discovery approach dubbed DynamixFit has let the firm select lead molecules with less than 100 compounds synthesized in under two years. Dynamix aims to apply its techniques on two main tracks: first, to discover drug candidates that intervene with the metabolism of cancer cells; and second, to selectively target specific cellular signaling pathways mediated by Type II kinase inhibitors.

You may also be interested in...

Cornerstone Pharmaceuticals Inc.

Cornerstone Pharmaceuticals Inc. is saying little about its lead drug candidate, CPI-613, which entered its first Phase I/II human clinical trial in late 2008, but the company and its backers believe they are developing a potentially game-changing class of new molecules and technology for delivering them. Its Altered Energy Metabolism Directed platform specifically utilizes the difference in cancer cells’ metabolic appetite to facilitate selective delivery of a novel small molecule (CPI-613 being the first example) into the cells’ mitochondria. Similarly the company’s Emulsiphan leverages those same metabolic differences to deliver drugs specifically to the cancer cell cytoplasm.

Advanced Cancer Therapeutics LLC

Advanced Cancer Therapeutics LLC is developing candidates against two cancer-metabolism targets. The first is PFKFB3, an enzyme that is believed to be a key player in glucose metabolism. Preclinical results suggest the compound inhibits tumors’ ability to consume glucose for growth and metastasis. ACT is also advancing a set of potential inhibitors against another key metabolic target called choline kinase, which is responsible for generating phosphocholine, one of the most important enzymes associated with choline metabolism and cell proliferation.

Biotechs Target Cancer Metabolism

As reseachers uncover linkages between tumor formation and cellular metabolism, start-ups and their venture backers see an opportunity to create a new class of cancer medicines. In this issue, we profile Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts